146 related articles for article (PubMed ID: 23761570)
1. Diabetic ketoacidosis: an unusual presentation of acromegaly.
Dosi RV; Patell RD; Shah PJ; Joshi HK
BMJ Case Rep; 2013 Jun; 2013():. PubMed ID: 23761570
[TBL] [Abstract][Full Text] [Related]
2. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly.
Haraguchi K; Ohtaka M; Takazawa K; Endo T; Onaya T
Endocr J; 1995 Apr; 42(2):295-300. PubMed ID: 7627275
[TBL] [Abstract][Full Text] [Related]
3. Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature.
Erem C; Ersöz HO; Ukinç K; Avunduk AM; Hacihasanoglu A; Koçak M
Endocrine; 2006 Aug; 30(1):145-9. PubMed ID: 17185803
[TBL] [Abstract][Full Text] [Related]
4. Concurrent diagnosis of acromegaly and diabetic ketoacidosis.
Westphal SA
Endocr Pract; 2000; 6(6):450-2. PubMed ID: 11155217
[TBL] [Abstract][Full Text] [Related]
5. Ketoacidosis as the initial clinical condition in nine patients with acromegaly: a review of 860 cases at a single institute.
Yoshida N; Goto H; Suzuki H; Nagasawa K; Takeshita A; Okubo M; Miyakawa M; Mori Y; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
Eur J Endocrinol; 2013 Jul; 169(1):127-32. PubMed ID: 23828957
[TBL] [Abstract][Full Text] [Related]
6. Evidence for dopamine agonists in the treatment of acromegaly.
Jaquet P
J Endocrinol; 1997 Oct; 155 Suppl 1():S59-60. PubMed ID: 9389998
[No Abstract] [Full Text] [Related]
7. Acromegaly presenting with diabetic ketoacidosis.
Katz JR; Edwards R; Khan M; Conway GS
Postgrad Med J; 1996 Nov; 72(853):682-3. PubMed ID: 8944212
[TBL] [Abstract][Full Text] [Related]
8. Proceedings of the workshop, "Practical approaches to the diagnosis and treatment of acromegaly".
Liuzzi A; Sobrinho LG; Besser GM
Metabolism; 1992 Sep; 41(9 Suppl 2):87-90. PubMed ID: 1518440
[TBL] [Abstract][Full Text] [Related]
9. Acromegaly in a woman presenting with diabetic ketoacidosis and insulin resistance.
Szeto CC; Li KY; Ko GT; Chow CC; Yeung VT; Chan JC; Cockram CS
Int J Clin Pract; 1997 Oct; 51(7):476-7. PubMed ID: 9536592
[TBL] [Abstract][Full Text] [Related]
10. Hyperthyroidism and acromegaly due to a thyrotropin- and growth hormone-secreting pituitary tumor. Lack of hormonal response to bromocriptine.
Carlson HE; Linfoot JA; Braunstein GD; Kovacs K; Young RT
Am J Med; 1983 May; 74(5):915-23. PubMed ID: 6340497
[TBL] [Abstract][Full Text] [Related]
11. [The treatment of acromegaly].
Beauregard H; Somma M; Rasio E; Serri O; Aris-Jilwan N; Comtois R; Long H; Abribat T; Boucher A; Hardy J
Union Med Can; 1993; 122(6):489-95. PubMed ID: 8303792
[TBL] [Abstract][Full Text] [Related]
12. Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR.
Resmini E; Murialdo G; Giusti M; Boschetti M; Minuto F; Ferone D
J Endocrinol Invest; 2005 Feb; 28(2):166-9. PubMed ID: 15887864
[TBL] [Abstract][Full Text] [Related]
13. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
Shimon I; Nass D; Hadani M
Pituitary; 2000 May; 2(4):289-94. PubMed ID: 11081151
[TBL] [Abstract][Full Text] [Related]
14. Pituitary gigantism causing diabetic ketoacidosis.
Alvi NS; Kirk JM
J Pediatr Endocrinol Metab; 1999; 12(6):907-9. PubMed ID: 10614552
[TBL] [Abstract][Full Text] [Related]
15. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
16. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
17. Pituitary macroadenoma presenting with pituitary apoplexy, acromegaly and secondary diabetes mellitus - a case report.
Nganga HK; Lubanga RP
Pan Afr Med J; 2013; 15():39. PubMed ID: 24062868
[TBL] [Abstract][Full Text] [Related]
18. Giant growth-hormone secreting pituitary tumour with extracranial extension.
Ip TP; Chan FL; Kung AW; Lam KS
Australas Radiol; 1996 Feb; 40(1):88-90. PubMed ID: 8838899
[TBL] [Abstract][Full Text] [Related]
19. [Effective treatment with constant subcutaneous infusion of octreotide in a patient with acromegaly associated with diabetic pre-coma and diabetes insipidus].
Abe T; Ohguni S; Tanigawa K; Kato Y
Nihon Naibunpi Gakkai Zasshi; 1994 Nov; 70(9):1029-38. PubMed ID: 7851621
[TBL] [Abstract][Full Text] [Related]
20. Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal.
Sadoul JL; Thyss A; Freychet P
Acta Endocrinol (Copenh); 1992 Feb; 126(2):179-83. PubMed ID: 1543025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
